参考文献/References:
[1] Zhang ZY, Wang ZM, Huang Y. Polycystic liver disease: classi- fication, diagnosis, treatment process, and clinical management[J]. World J Hepatol, 2020, 12: 72- 83.
[2] 阎洁羽,段 峰,王茂强. 选择性肝动脉栓塞治疗多囊肝的相关研究[J]. 介入放射学杂志, 2012, 21:1054- 1058.
[3] Roediger R, Dieterich D, Chanumolu P,et al. Polycystic kidney/liver disease[J]. Clin Liver Dis, 2022, 26: 229- 243.
[4] 南志宇,谢春明,冯对平,等. 超选择性肝动脉栓塞治疗症状性多囊肝临床效果[J]. 介入放射学杂志, 2015, 24:388- 391.
[5] Norcia LF,Watanabe EM,Hamamoto Filho PT,et al. Polycyctic liver disease: pathophysiology,diagnosis and treatment[J]. Hepat Med, 2022, 29:135- 161.
[6] van Aerts RMM, van de Laarschot LFM, Banales JM, et al. Clinical management of polycystic liver disease[J]. J Hepatol, 2018, 68: 827- 837.
[7] Masyuk TV, Masyuk AI, LaRusso NF. Polycystic liver disease: advances in understanding and treatment[J]. Annu Rev Pathol, 2022, 17: 251- 269.
[8] Wijnands TF, G?觟rtjes AP, Gevers TJ, et al. Efficacy and safety of aspiration sclerotherapy of simple hepatic cysts: a systematic review[J]. AJR Am J Roentgenol, 2017, 208: 201- 207.
[9] Miyayama S, Yamashiro M, Ikeda R, et al. Percutaneous sclerotherapy using a 4 F pigtail catheter and 40 milliliters of 5% ethanolamine oleate for symptomatic large hepatic cysts[J]. Diagn Interv Radiol, 2022, 28: 149- 155.
[10] Neijenhuis MK, Wijnands TFM, Kievit W, et al. Symptom relief and not cyst reduction determines treatment success in aspiration sclerotherapy of hepatic cysts[J]. Eur Radiol, 2019, 29: 3062- 3068.
[11] Calabrese GV, Waku M, Mazzarulli F, et al. Laparoscopic deroofing in large hepatic cyst with alcohol sclerotherapy. analysis of three cases[J]. Ann Ital Chir, 2022, 93: 224- 228.
[12] Wijnands TF, Ronot M, Gevers TJ, et al. Predictors of treatment response following aspiration sclerotherapy of hepatic cysts: an international pooled analysis of individual patient data[J]. Eur Radiol, 2017, 27: 741- 748.
[13] Takita M, Iwanishi M, Minami T, et al. Monoethanolamine oleate sclerotherapy for polycystic liver disease[J]. Dig Dis, 2016, 34: 654- 658.
[14] Iijima T, Suwabe T, Sumida K, et al. Prediction of hepatic cyst recurrence after minocycline hydrochloride aspiration sclerotherapy using cyst computed tomography values[J]. Hepatol Res, 2017, 47: 419- 424.
[15] Mavilia MG, Pakala T, Molina M, et al. Differentiating cystic liver lesions: a review of imaging modalities, diagnosis and management[J]. J Clin Transl Hepatol, 2018, 6: 208- 216.
[16] Yu JH, Du Y, Li Y, et al. Effectiveness of CT- guided sclerotherapy with estimated ethanol concentration for treatment of symptomatic simple hepatic cysts[J]. Clin Res Hepatol Gastroenterol, 2014, 38: 190- 194.
[17] Wijnands TF, Schoenemeier B, Potthoff A, et al. Ethanol sclerotherapy or polidocanol sclerotherapy for symptomatic hepatic cysts[J]. United European Gastroenterol J, 2018, 6: 919- 925.
[18] Wijnands TF,Gevers TJ, Kool LJ, et al. Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts(SCLEROCYST): study protocol for a randomized controlled trial[J]. Trials, 2015, 16: 82.
[19] Coussy A, Jambon E, Le Bras Y, et al. The safety and efficacy of hepatic transarterial embolization using microspheres and microcoils in patients with symptomatic polycystic liver disease[J]. J Pers Med, 2022, 12: 1624.
[20] Yan JY, Zhang JL, Yuan K, et al. Transarterial embolisation with bleomycin and N- butyl- 2- cyanoacrylate- lipiodol mixture for symptomatic polycystic liver disease: preliminary experience[J]. Clin Radiol, 2019, 74: 975.e11- e16.
[21] Zhang JL, Yuan K, Wang MQ, et al. Transarterial embolization for treatment of symptomatic polycystic liver disease: more than 2- year follow- up[J]. Chin Med J(Engl), 2017, 130: 1938- 1944.
[22] Sakuhara Y, Nishio S, Hattanda F, et al. Initial experience with the use of tris- acryl gelatin microspheres for transcatheter arterial embolization for enlarged polycystic liver[J]. Clin Exp Nephrol, 2019, 23: 825- 833.
[23] Hoshino J, Ubara Y, Suwabe T, et al. Intravascular embolization therapy in patients with enlarged polycystic liver [J]. Am J Kidney Dis, 2014, 63: 937- 944.
[24] Wang MQ, Duan F, Liu FY, et al. Treatment of symptomatic polycystic liver disease: transcatheter super- selective hepatic arterial embolization using a mixture of NBCA and iodized oil[J]. Abdom Imaging, 2013, 38: 465- 473.
[25] 袁 冰,阎洁羽,王茂强,等. 两种栓塞方法行超选择性肝动脉栓塞术治疗多囊肝病的对比研究[J]. 中华肝胆外科杂志,2019, 25:505- 508.
[26] Wakui N, Takeda Y, Nishinakagawa S, et al. Effect of obstructive jaundice on hepatic hemodynamics: use of sonazoid- enhanced ultrasonography in a prospective study of the blood flow balance between the hepatic portal vein and hepatic artery[J]. J Med Ultrason(2001), 2015, 42: 513- 520.
[27] Li H, Ge N, He C, et al. Portal vein embolization in the treatment of portal vein bleeding after percutaneous transhepatic biliary drainage: a case report and literature review[J]. J Interv Med, 2022, 5: 217- 220.
[28] Zhang G, Wang M, Duan F, et al. Early- and intermediate- term outcome of transarterial embolization for symptomatic hepatic focal nodular hyperplasia[J]. J Interv Med, 2018, 1: 86- 91.
相似文献/References:
[1]南志宇,谢春明,冯对平,等.超选择性肝动脉栓塞治疗症状性多囊肝临床效果[J].介入放射学杂志,2015,(05):388.
NAN Zhi yu,XIE Chun ming,FENG Dui ping,et al.The clinical efficacy of transcatheter super selective hepatic artery embolization for the treatment of symptomatic polycystic liver disease[J].journal interventional radiology,2015,(02):388.